UBS has released a research report projecting that the median revenue growth for rated healthcare companies will reach 16% in 2025 and 10% in 2026, based on the latest industry sales data and licensing transactions. The bank expects most companies' core product sales to meet or exceed its forecasts. UBS has replaced HANSOH PHARMA with 3SBIO as its top pick, assigning 3SBIO a "buy" rating and a target price of HK$41, citing reasonable valuation. Looking ahead to 2026, the bank anticipates median sector revenue growth of 10%, supported by steady sales growth of innovative drugs and promising R&D progress. UBS also raised target prices for several stocks: CSPC PHARMA's target was increased from HK$10 to HK$10.9, HANSOH PHARMA's from HK$48.2 to HK$51.5, and HENGRUI PHARMA's from HK$96.9 to HK$98.3. The respective ratings assigned are "neutral," "buy," and "buy."